

Clinical trials of mibefradil

TrialResults-center www.trialresultscenter.org

1 heart failure

Trial	Treatments	Patients	Trials design and methods
mibefradil vs placebo			
MACH 1 , 2000 n=1295/1295 follow-up: 1.6 years	mibefradil titrated up to 100mg daily versus placebo	Patients with moderate to severe congestive heart failure (NYHA class II to IV and left ventricular fraction ,35%).pj	Parallel groups Double aveugle US, Canada, Europe and Israel

More details and results :

- calcium channel blockers for heart failure in all type of patients at <http://www.trialresultscenter.org/go-Q70>

References

MACH 1, 2000:

Levine TB, Bernink PJ, Caspi A, Elkayam U, Geltman EM, Greenberg B, McKenna WJ, Ghali JK, Giles TD, Marmor A, Reisin LH, Ammon S, Lindberg E Effect of mibefradil, a T-type calcium channel blocker, on morbidity and mortality in moderate to severe congestive heart failure: the MACH-1 study. Mortality Assessment in Congestive Heart Failure Trial. Circulation 2000 Feb 22;101:758-64 [[10683349](#)]